181 related articles for article (PubMed ID: 21428921)
1. The tuberous sclerosis complex: balancing proliferation and survival.
Tomasoni R; Mondino A
Biochem Soc Trans; 2011 Apr; 39(2):466-71. PubMed ID: 21428921
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
4. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
6. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
7. Proteins interacting with the tuberous sclerosis gene products.
Rosner M; Freilinger A; Hengstschläger M
Amino Acids; 2004 Oct; 27(2):119-28. PubMed ID: 15351877
[TBL] [Abstract][Full Text] [Related]
8. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment.
de Vries PJ; Howe CJ
Trends Mol Med; 2007 Aug; 13(8):319-26. PubMed ID: 17632034
[TBL] [Abstract][Full Text] [Related]
9. Tuberin activates the proapoptotic molecule BAD.
Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
[TBL] [Abstract][Full Text] [Related]
10. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
11. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
[TBL] [Abstract][Full Text] [Related]
12. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners.
Rosner M; Hanneder M; Siegel N; Valli A; Hengstschläger M
Mutat Res; 2008; 658(3):234-46. PubMed ID: 18291711
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.
Soucek T; Rosner M; Miloloza A; Kubista M; Cheadle JP; Sampson JR; Hengstschläger M
Oncogene; 2001 Aug; 20(35):4904-9. PubMed ID: 11521203
[TBL] [Abstract][Full Text] [Related]
14. Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Karbassi I; Batish SD; den Dunnen JT; van Eeghen A; Thiele E; Mayer K; Dies K; Wen L; Thompson C; Sparagana SP; Davies P; Aalfs C; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2012 Mar; 33(3):476-9. PubMed ID: 22161988
[TBL] [Abstract][Full Text] [Related]
15. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
16. A reliable cell-based assay for testing unclassified TSC2 gene variants.
Coevoets R; Arican S; Hoogeveen-Westerveld M; Simons E; van den Ouweland A; Halley D; Nellist M
Eur J Hum Genet; 2009 Mar; 17(3):301-10. PubMed ID: 18854862
[TBL] [Abstract][Full Text] [Related]
17. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
18. Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex.
Mizuguchi M
Congenit Anom (Kyoto); 2007 Mar; 47(1):2-8. PubMed ID: 17300684
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
[TBL] [Abstract][Full Text] [Related]
20. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
Lee L; Sudentas P; Dabora SL
Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
